A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin.
In a double-blind, placebo-controlled, randomized group comparison, new and specific biochemical markers for bone resorption as follow-up parameters on the therapeutic response to nasal salmon calcitonin (sCT) were evaluated. Evaluation took place at an outpatient clinic where osteoporosis was being researched. The subjects included 208 women aged 68-72 treated for 2 years with either 50 IU, 100 IU, or 200 IU of nasal sCT or placebo; all groups received a daily calcium supplementation of 500 mg. Only 164 women fulfilled the study as valid completers. Markers were applied to frozen urine samples of a previously published intervention study of a new fasting urinary (fU) biochemical marker for bone resorption (CrossLapstrade mark, ELISA) and the urinary excretion of cross-links (pyridinoline and deoxypyridinoline) was measured, all corrected for creatinine. Bone mineral density of the lumbar spine and rates of vertebral and peripheral fractures were measured after 2 years of treatment. The creatinine corrected urinary pyridinoline, deoxypyridinoline, and CrossLaps showed maximum decreases of 10-43% (95% confidence interval -29.5% to 9.6% and -75.1% to 9.3%; P < 0. 01-0.001) after 6-9 months, after which the response leveled off. A significant difference among the four treatment groups was seen in fU CrossLaps (P < 0.01). The changes in spinal bone mass were significantly related to the decreases in fU CrossLaps: women with the highest response in spinal bone mass had decreases in fU CrossLaps of 44% (-83.5% to 7.4%) and women without response of 5% (-57.6% to 99.9%) P < 0.001). In women who fractured during the 2-year period, fU CrossLaps remained unchanged, whereas decreases of 30% (-75.1% to 44.7%) were seen in women who did not fracture (P = 0. 002). The results suggest that biochemical markers can be used to determine the optimum treatment regimen of nasal sCT. The response of the new marker, fU CrossLaps, significantly reflects the responses in bone mass of the spine and fracture rates.
Overgaard
K
K
Center for Clinical & Basic Research, Ballerup Byvej 222, Ballerup, DK-2750 Denmark.
Christiansen
C
C
D000281:Administration, Intranasal; D000368:Aged; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000652:urine*; D015519:Bone Density / Q000502:physiology; D001862:Bone Resorption / Q000188:drug therapy* / Q000652:urine; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans
D000596:Amino Acids; D015415:Biomarkers; C015484:pyridinoline; C028815:salmon calcitonin; C036020:deoxypyridinoline; D002116:Calcitonin